Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A

Jennifer Pocoski,1 Nanxin Li,2 Rajeev Ayyagari,2 Nikki Church,1 Monika Maas Enriquez,1 Quer Xiang,2 Sneha Kelkar,3 Ella X Du,2 Eric Q Wu,2 Jipan Xie3 1Bayer HealthCare Pharmaceuticals, Whippany, NJ, 2Analysis Group, Inc., Boston, MA, 3Analysis Group, Inc., New York, NY, USA Background: No head-to-he...

Full description

Bibliographic Details
Main Authors: Pocoski J, Li N, Ayyagari R,Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J
Format: Article
Language:English
Published: Dove Medical Press 2016-07-01
Series:Journal of Blood Medicine
Subjects:
hemophilia a
recombinant factor VIII
annualized bleed rate
indirect comparison
efficacy
prophylaxis
Online Access:https://www.dovepress.com/matching-adjusted-indirect-comparisons--of-efficacy-of-bay-81-8973-vs--peer-reviewed-article-JBM

Internet

https://www.dovepress.com/matching-adjusted-indirect-comparisons--of-efficacy-of-bay-81-8973-vs--peer-reviewed-article-JBM

Similar Items